Evidence map›Paper›PMID 41612371›Full record

SynthesisWorld journal of surgical oncology2026

Effect of hyperthermic intraperitoneal chemotherapy on patients with advanced colorectal cancer: a systematic review and meta-analysis.

Ziying Su, Yong Guo, Xiaosong Ru, Xiao Wang, Qiaoran Mao, Nuo Zhou, Zhili Xu, Luyi Huang, Chenyu Ge, Yaonan Hong and 2 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ziying SuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Yong GuoThe First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Xiaosong RuDepartment of Traditional Chinese Medicine, Hebei General Hospital, Shijiazhuang, China.
Xiao WangThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Qiaoran MaoThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Nuo ZhouThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Zhili XuThe First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Luyi HuangThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Chenyu GeThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Yaonan HongThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Fule HeZhejiang Chinese Medicine Museum, Zhejiang Chinese Medical University, Hangzhou, China. hefule@163.com.
Meilan HuDepartment of Prevention and Health, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China. humeilan2025@163.com.

Funding

Zhejiang Chinese Medical University 2025 Zhejiang Chinese Medical University Cultivation Plan for Top Innovative Talents of Postgraduates (No. 2025YJSBJ008)
6 · The paper itself

Abstract

backgroundAdvanced colorectal cancer (CRC) predisposes to peritoneal metastases (PM), leading to a decreased survival rate. Advanced CRC includes CRC with PM (CRC-PM) and locally advanced high-risk CRC without PM. The effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) in prolonging survival and in treating or preventing PM after surgery for advanced CRC is still uncertain.

methodsA search of PubMed, Cochrane, Embase, and Web of science databases for relevant studies prior to April 2024 was performed. Data were analyzed using Stata/MP 17.0 software. The primary outcomes included overall survival (OS) and disease-free survival (DFS). Secondary outcomes were overall recurrence rate (ORR), PM rate, and complications. The quality of evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluations (GRADE).

resultsA total of ten high-quality cohort studies and four randomized controlled trials (RCTs) were included, encompassing 2851 patients. HIPEC improved 1-year DFS (odds ratio (OR) = 1.64, 95%Cl: 1.09–2.46) and 5-year OS (OR = 1.49, 95%Cl: 1.10–2.03) in advanced CRC. HIPEC also reduced the overall PM rate (OR = 0.66, 95%Cl: 0.49–0.90). For advanced high-risk CRC without prior PM, HIPEC reduced the PM rate and had a preventive effect (OR = 0.71, 95%Cl: 0.52–0.97). In terms of complications, HIPEC increased the incidence of thrombopenia (OR = 5.77, 95%Cl: 1.65–20.09) and neutropenia (OR = 3.21, 95%Cl: 1.74–5.90). The quality of evidence ranged from high to very low.

conclusionThe use of HIPEC in treating advanced CRC may result in improved survival rates and a reduction in peritoneal recurrence or metastasis, although complications should be considered. Further investigation is required to clarify the role of HIPEC in more high-quality RCTs.

Indexed as

Colorectal NeoplasmsHyperthermia, InducedHyperthermic Intraperitoneal ChemotherapyNeoplasm Recurrence, LocalPeritoneal NeoplasmsHumansPrognosisSurvival RateColorectal cancerComplicationsHyperthermic intraperitoneal chemotherapyRecurrenceSurvival

Identifiers

PMID41612371
PMCPMC12980965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.